TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05272189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated Second Reader AI
Description: In this experiment, in some conditions, the participant makes their decision in the presence of information about a simulated artificial intelligence decision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Target Prevalence
Description: The frequency with which targets are presented varies from 10% to 90%
Study: NCT05999331

Intervention type: OTHER
Intervention: initial aspartate aminotransferase (AST) to platelet (PLT) ratio index
Description: All eligible patients were given antibiotics therapy, actively control infection source, as well as other supportive therapy to maintain organ function.
Study: NCT00920998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-338
Description: oral
Study: NCT01571622

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey before Breakfast
Description: After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
Study: NCT03627494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study: NCT01571622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey before Breakfast
Description: After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
Study: NCT01571622

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water before breakfast
Description: After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water before breakfast
Description: After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
Study: NCT04631809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-Coronary Angiography + Coronary angiography +/- percutaneous coronary intervention
Description: Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
Study: NCT05158920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy for Suicidal individuals (MBCT-S)
Description: MBCT-S is a group intervention of 8 weekly sessions of 2 hours combining techniques of mindfulness with important elements of cognitive therapy (e.g. safety plan and homework).
Study: NCT03627494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study: NCT03692143

Intervention type: PROCEDURE
Intervention: PVP
Description: With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously

Intervention type: PROCEDURE
Intervention: PVP
Description: With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously

Intervention type: DRUG
Intervention: Alendronate
Description: Alendronate Sodium, oral, 70mg, once a week
Study: NCT01403974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Intravenous infusion once every week
Study: NCT03428724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation
Description: standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized Preparation
Description: individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age\>65, neurologic comorbidities)
Study: NCT02499822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Description: Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
Study: NCT03896386

Intervention type: OTHER
Group type: OTHER
Intervention: Use of seizure diary
Description: The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end
Study: NCT03390816

Intervention type: OTHER
Intervention: Nutritional assessment
Description: Observational

Intervention type: OTHER
Intervention: Nutritional assessment
Description: Observational
Study: NCT04269252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHI-907
Description: CHI-907 is a high CBD extract.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHI-907
Description: CHI-907 is a high CBD extract.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHI-907
Description: CHI-907 is a high CBD extract.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CHI-804
Description: CHI-804 is the placebo formulation.
Study: NCT01703039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Study: NCT01703039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT01523535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: repeated cycles of short sleep
Description: - 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: repeated cycles of short sleep
Description: - 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
Study: NCT05799742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral hernioplasty
Study: NCT02787031

Intervention type: PROCEDURE
Intervention: Neuraxial anesthesia

Intervention type: PROCEDURE
Intervention: General anesthesia
Study: NCT02009215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
Study: NCT01692483

Intervention type: DRUG
Intervention: Abiraterone acetate
Description: Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily

Intervention type: DRUG
Intervention: Prednisone
Description: Prednisone or prednisolone 5 mg tablet taken orally twice daily
Study: NCT00698919

Intervention type: OTHER
Intervention: Observational study
Description: This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision.

Intervention type: OTHER
Intervention: Observational study
Description: This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision.
Study: NCT02545738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: active treatment
Study: NCT03627494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study: NCT00886574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 200 mg (50 mg 2T twice per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100 mg once a day
Study: NCT03592342

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clobetasol Propionate
Description: Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
Study: NCT03594695

Intervention type: DIAGNOSTIC_TEST
Intervention: HSCRP and NLR
Description: hs-CRP levels and NLR values will be studied from routine blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: HSCRP and NLR
Description: hs-CRP levels and NLR values will be studied from routine blood samples.
Study: NCT01834430

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition
Study: NCT02925585

Intervention type: OTHER
Intervention: Pre/post imaging
Study: NCT03056261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined general and epidural
Description: Combined general and epidural anaesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: General anaesthesia
Description: General anaesthesia
Study: NCT01237353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: betaine hydrochloride
Description: betaine hydrochloride 1500mg po x 1 on day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: rabeprazole po daily x 5 days
Study: NCT04570397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
Study: NCT04449757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicarbonated Ringer's solution
Description: Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Description: Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
Study: NCT01530594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide/Low dose Dex
Description: Lenalidomide/Low dose Dex (LLD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib/Lenalidomide/ Low dose Dex
Description: Bortezomib/Lenalidomide/ Low dose Dex (BLLD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide/Low dose Dex (LLD
Study: NCT02353052

Intervention type: OTHER
Intervention: follow up
Description: The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).

Intervention type: OTHER
Intervention: follow up
Description: The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
Study: NCT01150890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Administered as as an intravenous (IV) infusion over at least 30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Administered as as an intravenous (IV) infusion over at least 30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Administered as as an intravenous (IV) infusion over at least 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as as an intravenous (IV) infusion over at least 30 minutes.
Study: NCT01303536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
Study: NCT03340870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid™
Description: Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid™
Description: Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
Study: NCT01747720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02243839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thrombolytic Therapy
Description: Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Redo valve surgery is performed for obstructive valve thrombosis
Study: NCT01629966

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone, 20mg, oral administration once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone, 40mg, oral administration once per day.
Study: NCT02643017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
Study: NCT01911663

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KRG
Description: 500 mg Korea red ginseng (KRG)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg placebo
Study: NCT03771937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and telephone follow-up intervention
Description: A telephone follow up and a pre-discharge education
Study: NCT02006628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42003
Description: GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
Study: NCT01809483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bandage contact lens
Description: Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure patching
Description: Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
Study: NCT02252783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFPET
Description: Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
Study: NCT01849198

Intervention type: DEVICE
Group type: OTHER
Intervention: accelerometry m. trapezius and m. adductor pollicis

Intervention type: DEVICE
Group type: OTHER
Intervention: accelerometry m. trapezius and m. adductor pollicis
Study: NCT01652209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hearticellgram-AMI
Study: NCT02939430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex intravenous
Description: Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous neostigmine and atropine
Study: NCT00702195

Intervention type: DRUG
Intervention: Org 36286 (corifollitropin alfa)
Description: single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807

Intervention type: DRUG
Intervention: Org 36286 (corifollitropin alfa)
Description: single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807

Intervention type: DRUG
Intervention: Placebo
Description: single dose of placebo (administered under protocol 38805)

Intervention type: DRUG
Intervention: recFSH
Description: 150 IU recFSH daily (reference group administered under protocol 38807)
Study: NCT03159624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodesign™ SIS graft
Description: 2x3 cm Biodesign™ SIS perforated mesentery graft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Doyle silastic sheet
Description: Doyle silastic sheet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doyle silastic sheet
Description: Doyle silastic sheet
Study: NCT03906838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
Study: NCT02044393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: multiple doses of itraconazole given as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: single dose BI 691751 given as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: single dose BI 691751 given as tablet
Study: NCT01086722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: karolinska cocktail
Description: The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol
Study: NCT03940040

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Description: High flow nasal oxygen
Study: NCT03133169

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level

Intervention type: DIAGNOSTIC_TEST
Intervention: Tricuspid regurge velocity
Description: Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children

Intervention type: DIAGNOSTIC_TEST
Intervention: Tricuspid regurge velocity
Description: Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children

Intervention type: DIAGNOSTIC_TEST
Intervention: Tricuspid regurge velocity
Description: Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
Study: NCT03627494

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards